Systematic review of migraine prophylaxis adherence and persistence

Journal of Managed Care Pharmacy

Volumn 20, Issue 1, 2014, Pages 22-33

  Hepp, Zsolt ^a   Bloudek, Lisa M ^a   Varon, Sepideh F ^b  

^a Global Health Outcomes Strategy and Research   (United States)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; PROPRANOLOL; TOPIRAMATE;

ANALGESIA; CHEMOPROPHYLAXIS; DRUG WITHDRAWAL; HUMAN; MEDICATION COMPLIANCE; MIGRAINE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; HUMANS; MEDICATION ADHERENCE; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84890876183     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.1.22     Document Type: Review

References (49)

1. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-49.
2. Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value Health. 2009;12(1):55-64.
3. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. US Headache Consortium. Available at: http://tools.aan.com/professionals/practice/pdfs/gl0090.pdf. Accessed November 18, 2013.
4. Kowacs PA, Piovesan EJ, Tepper SJ. Rejection and acceptance of possible side effects of migraine prophylactic drugs. Headache. 2009;49(7):1022-27.
5. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
6. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.
7. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728-40. Available at: http://amcp.org/WorkArea/DownloadAsset.aspx?id=8250.
8. Thier SL, Yu-Isenberg KS, Leas BF, et al. In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines. Manag Care. 2008;17(2):48-52, 55-57.
9. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794-811.
10. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200-09.
11. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47.
12. Mulleners WM, Whitmarsh TE, Steiner TJ. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia. 1998;18(1):52-56.
13. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.
14. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004;42(7):649-52.
15. Nichol MB, Venturini F, Sung JC. A critical evaluation of the methodology of the literature on medication compliance. Ann Pharmacother. 1999;33 (5):531-40.
16. Gaul C, van Doorn C, Webering N, et al. Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. J Headache Pain. 2011;12(4):475-83.
17. Heckman BD, Ellis G. Preventive medication adherence in African American and Caucasian headache patients. Headache. 2011;51(4):520-32.
18. Rothrock JF, Parada VA, Sims C, Key K, Walters NS, Zweifler RM. The impact of intensive patient education on clinical outcome in a clinic-based migraine population. Headache. 2006;46(5):726-31.
19. Lafata JE, Tunceli O, Cerghet M, Sharma KP, Lipton RB. The use of migraine preventive medications among patients with and without migraine headaches. Cephalalgia. 2010;30(1):97-104.
20. Berger A, Varon SF, Bramley TJ, et al. Adherence with pharmacological prophylaxis of migraine. Cephalalgia. 2009;29(Suppl 1):S56.
21. Nelles G, Schmitt L, Humbert T et al. Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting. J Headache Pain. 2010;11(1):33-44.
22. Malessa R, Gendolla A, Steinberg B, et al. Prevention of episodic migraine with topiramate: a prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting. Curr Med Res Opin. 2010;26(5):1119-29.
23. Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci. 2004;25(5):245-50.
24. Lampl C, Huber G, Adl J, et al. Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors. Eur J Neurol. 2009;16(8):943-48.
25. Krymchantowski AV, Jevoux CC. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study. Headache. 2011;51(4):554-58.
26. Verspeelt J, De Locht P, Amery WK. Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Cephalalgia. 1996;16(5):328-36, discussion 288.
27. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC. Migraine prophylactic medication usage patterns in The Netherlands. Cephalalgia. 2003;23(4):293-301.
28. Yaldo AZ, Wertz DA, Rupnow MF, Quimbo RM. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting. Clin Ther. 2008;30(12):2452-60.
29. Zeller A, Ramseier E, Teagtmeyer A, Battegay E. Patients' self-reported adherence to cardiovascular medication using electronic monitors as comparators. Hypertens Res. 2008;31(11):2037-43.
30. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, selfreport, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother. 1998;32(7-8):749-54.
31. Mohammadianinejad SE, Abbasi V, Sajedi SA. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol. 2011;34(4):174-77.
32. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multicenter double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51(1):21-32.
33. Couch JR. Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51(1):33-51.
34. Rodríguez-Leyva I, Sánchez-Aguilar MC, Hernández-Sierra JF et al. Topiramate vs. amitriptyline in prophylactic treatment of migraine: a controlled clinical trial. Revista Mexicana de Neurociencia. 2010;11(5):338-42.
35. Domingues RB, Silva AL, Domingues SA, Aquino CC, Kuster GW. A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. Arq Neuropsiquiatr. 2009;67(4):973-77.
36. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009;31(3):542-59.
37. Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med. 2008;9(2):175-85.
38. Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand. 2008;118(5):301-5.
39. Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008;110(10):979-84.
40. Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache. 2002;42(6):510-14.
41. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia. 2002;22(3):209-21.
42. Rao BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India. 2000;48(3):223-26.
43. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol. 1997;54(9):1141-45.
44. Bánk J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache. 1994;34(8):476-78.
45. Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia. 1989;9(4):247-53.
46. Mikkelsen B, Pedersen KK, Christiansen LV. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neurol Scand. 1986;73(4):423-27.
47. Ryan RE Sr. Comparative study of nadolol and propranolol in prophylactic treatment of migraine. Am Heart J. 1984;108(4 Pt 2):1156-59.
48. Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand. 1984;69(1):1-8.
49. Andersson PG, Petersen EN. Propranolol and femoxetine, a HT-uptake inhibitor, in migraine prophylaxis. A double-blind crossover study. Acta Neurol Scand. 1981;64(4):280-88.